Lepu Biopharma (HKG:2157) granted Nasdaq-listed ArriVent BioPharma an exclusive license to develop and commercialize any product with MRG007 globally outside of the Greater China region, according to a Wednesday filing with the Hong Kong Exchange.
MRG007 is indicated for gastrointestinal cancers, the filing said.
ArriVent will also get a non-exclusive license under certain intellectual property controlled by Lepu to develop, manufacture, and commercialize products containing MRG007 for anti-cancer use in other places except Greater China, the filing said.
Lepu will be entitled to a one-time upfront payment and near-term milestone payments of $47 million.
The company will also be eligible for up to $1.16 billion in development, regulatory and sales milestones, and tiered royalties of high single digits to low-teen percentages on net sales outside of China, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.